On January 5, 2022 Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, reported that Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the JP Morgan Healthcare Meeting held virtually on January 10-13, 2022 (Press release, Invectys, JAN 5, 2022, View Source [SID1234598223]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to the main meeting, Dr. Tyle will also attend Biotech ShowcaseTM, virtually from January 10-19. He will present an overview of all of Invectys’ projects to date on January 11th, at 9:15 am Pacific time. The presentation has already been posted on the Biotech Showcase website.